Badlands Resources Inc (PK) (BDLNF) News

Form 8-K - Current report

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan...

Form 8-K - Current report

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent...

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that...

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the...

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84...

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and...

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments Ongoing Phase 3 RAMP 301 trial is evaluating...

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

 GFH375 (VS-7375), a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, demonstrated potent anti-tumor activity in pancreatic and...